On this page
ALPS type Ia
Autoimmune Lymphoproliferative Syndrome type Ia (ALPS type Ia) is a rare genetic condition that primarily affects the immune system. It causes an overproduction of lymphocytes, leading to enlarged lymph nodes, spleen, and an increased risk of autoimmune problems and certain cancers.
Overview
Autoimmune Lymphoproliferative Syndrome type Ia (ALPS type Ia) is a rare genetic condition impacting the immune system's delicate balance. Normally, the body's immune cells, called lymphocytes, are produced to fight infections and then programmed to die off once their job is done. In ALPS type Ia, this process of programmed cell death (apoptosis) is disrupted in certain lymphocytes [PMID:33675037]. This failure of immune cells to die off as expected results in their accumulation, primarily in the lymph nodes, spleen, and liver. This can lead to these organs becoming enlarged.
ALPS type Ia is one form of a broader group of disorders known as ALPS. It is an inherited condition, meaning it is passed down through families. While it can cause a range of health issues, including autoimmune problems, with appropriate medical care, many individuals with ALPS type Ia can lead fulfilling lives.
Symptoms & clinical features
The main clinical features of ALPS type Ia often include enlarged lymph nodes (lymphadenopathy), an enlarged spleen (splenomegaly), and sometimes an enlarged liver (hepatomegaly). These enlargements can be persistent or occur in episodes. Another characteristic finding often seen in ALPS is an increase in a specific type of T-lymphocyte called double-negative T cells (DNT cells) in the blood [PMID:33675037].
Around 70% of individuals with ALPS develop autoimmune conditions [PMID:27063462]. The most common autoimmune issues in ALPS include a type of anaemia where the immune system attacks red blood cells (autoimmune haemolytic anaemia), a condition where platelets are destroyed (immune thrombocytopenia), and a disorder affecting white blood cells (autoimmune neutropenia). Less commonly, autoimmune conditions affecting other parts of the body, such as the liver, kidneys, or nerves, may also occur.
Video: Genetics 101
Affected organs
ALPS type Ia primarily affects the organs of the immune system. The most commonly affected organs are the lymph nodes, which can become noticeably swollen and palpable. The spleen is also frequently enlarged, sometimes significantly, which can lead to discomfort or other complications. The liver may also become enlarged. These organ enlargements are due to the accumulation of lymphocytes.
Beyond these, the blood-forming system is significantly impacted, leading to various autoimmune blood conditions. In some cases, other organs can be affected if autoimmune responses target them, for example, the kidneys or nervous system, although these are less common.
Risks & severity
The severity of ALPS type Ia symptoms can vary considerably between individuals, even within the same family. Some people may experience mild, intermittent lymph node enlargement, while others might have more severe and persistent symptoms, including significant autoimmune complications. The risk of developing autoimmune conditions is substantial, with autoimmune haemolytic anaemia, immune thrombocytopenia, and autoimmune neutropenia being the most frequent.
Individuals with ALPS type Ia also have an increased risk of developing certain cancers, particularly Hodgkin lymphoma and non-Hodgkin lymphoma [PMID:27063462]. This increased risk is thought to be related to the long-standing accumulation of lymphocytes and the chronic immune dysregulation. The lifetime risk of lymphoma is approximately 20-30%. Regular follow-up with specialist doctors is crucial to monitor for these potential complications.
Genetic causes
ALPS type Ia is caused by specific changes in the FAS gene. The FAS gene provides instructions for making a protein that plays a critical role in controlling programmed cell death, also known as apoptosis. Apoptosis is a vital natural process where cells are signalled to die and be removed from the body when they are no longer needed, are damaged, or are potentially harmful. This process is essential for maintaining healthy tissues and the proper functioning of the immune system.
The FAS protein acts as a 'death receptor' on the surface of cells. When it binds to a specific ligand (FASL), it triggers a signalling pathway that leads to the cell's destruction. In individuals with ALPS type Ia, the genetic changes in the FAS gene lead to a faulty or absent FAS protein, which means the apoptotic pathway cannot be properly activated in certain lymphocytes. This defect prevents these immune cells from undergoing programmed cell death, leading to their accumulation in various tissues and organs and contributing to the symptoms of ALPS type Ia.
- FAS Fas cell surface death receptor
Inheritance pattern
ALPS type Ia typically follows an autosomal dominant inheritance pattern. This means that a person only needs one copy of the altered FAS gene in each cell to develop the condition. In most cases, an affected individual inherits the altered gene from one parent who also has the condition. However, it is also possible for ALPS type Ia to occur due to a new (de novo) genetic change in the FAS gene, meaning neither parent carries the altered gene. When a parent has ALPS type Ia, there is a 50% chance with each pregnancy that their child will inherit the altered gene and therefore be affected by the condition, regardless of the child's sex.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosing ALPS type Ia often begins with a clinical evaluation based on the characteristic symptoms, such as enlarged lymph nodes and spleen, and recurrent or unusual autoimmune issues. Laboratory tests will typically show an increased number of double-negative T cells (DNT cells) in the blood, which is a strong indicator of ALPS [PMID:33675037]. Elevated levels of specific blood markers, such as soluble FAS ligand (sFASL), interleukin-10 (IL-10), and vitamin B12, can also support a diagnosis.
Confirmation of ALPS type Ia is achieved through genetic testing of the FAS gene. Genetic testing for ALPS is available through the NHS Genomic Medicine Service, typically following a referral from a specialist consultant. Relevant R-codes for genetic testing may include R144 (for ALPS and related disorders). Clinical geneticists or immunology specialists are generally involved in coordinating these referrals and interpreting the results.
Management & lifestyle
Management of ALPS type Ia focuses on monitoring symptoms, treating autoimmune complications, and preventing or detecting lymphoma early. care for ALPS type Ia is individualised and should always be guided by specialist doctors, typically immunologists or haematologists. Regular monitoring for enlarged lymph nodes, spleen, and blood abnormalities, including DNT cell counts, is usually recommended.
Treatment for autoimmune manifestations often involves immunosuppressive medications such as corticosteroids or other drugs to dampen the immune response. In some cases of severe spleen enlargement or very difficult-to-treat autoimmune conditions, a splenectomy (surgical removal of the spleen) may be considered, although this is now less common due to improved medical therapies. Regular follow-up is essential to screen for the development of lymphoma and to manage any emerging symptoms or complications.
UK care pathway
In the UK, individuals suspected of having ALPS type Ia are typically referred to specialist immunology or haematology services. These specialists, often based in larger NHS hospitals, would then guide further investigations and management. If ALPS type Ia is suspected, genetic testing can be requested through the NHS Genomic Medicine Service (GMS) pathways. Referrals for genetic testing usually come from a consultant and will use specific R-codes, such as R144, to ensure appropriate testing. Genetic counsellors play a crucial role in supporting individuals and families through the diagnostic process, explaining inheritance patterns, and discussing potential implications.
Frequently asked questions
What does 'lymphoproliferative' mean?
'Lymphoproliferative' refers to the excessive production and accumulation of lymphocytes, which are a type of white blood cell. In ALPS, these cells don't die off normally, leading to their build-up in organs like the lymph nodes and spleen.
Is ALPS type Ia a cancer?
No, ALPS type Ia is not a cancer itself, but it does increase the risk of developing certain types of lymphoma (a cancer of the immune system) later in life. Regular monitoring is important for early detection.
If I have ALPS type Ia, will my children have it?
ALPS type Ia is usually inherited in an autosomal dominant pattern. If you have the condition, there is a 50% chance with each pregnancy that your child will inherit the genetic change and may develop the condition.
Are there specific dietary recommendations for ALPS type Ia?
Currently, there are no specific dietary recommendations uniquely proven to manage ALPS type Ia. A healthy, balanced diet is generally advised, and any specific dietary changes should be discussed with a doctor or dietitian.
Can ALPS type Ia go away on its own?
ALPS type Ia is a lifelong genetic condition. While some symptoms, such as enlarged lymph nodes, can fluctuate, the underlying genetic cause remains. Management focuses on controlling symptoms and preventing complications, rather than a cure.
References
- Guégan JP, Legembre P. Nonapoptotic functions of Fas/CD95 in the immune response. The FEBS journal. 2018. PMID: 29032605
- van der Werff ten Bosch J, Otten J, Thielemans K. Autoimmune lymphoproliferative syndrome type III, an indefinite disorder. Leukemia & lymphoma. 2001. PMID: 11378568
- Van Der Werff Ten Bosch J, Otten J, Thielemans K. Autoimmune lymphoproliferative syndrome type III: an indefinite disorder. Leukemia & lymphoma. 2001. PMID: 11342357
- Bleesing JJ, Brown MR, Straus SE. Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood. 2001. PMID: 11588044
- Dowdell KC, Niemela JE, Price S. Somatic FAS mutations are common in patients with genetically undefined autoimmune lymphoproliferative syndrome. Blood. 2010. PMID: 20360470
- Vacek MM, Schäffer AA, Davis J. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia). Clinical immunology (Orlando, Fla.). 2006. PMID: 16257267
- Maric I, Pittaluga S, Dale JK. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. The American journal of surgical pathology. 2005. PMID: 15958855
- Legembre P, Barnhart BC, Zheng L. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO reports. 2004. PMID: 15514680